Eli Lilly (LLY) stock rises after reporting that sales of its weight-loss drugs more than doubled in the third quarter. The ...

Eli Lilly beats Q3 2025 estimates and raises guidance as strong GLP-1 drug sales from Mounjaro and Zepbound lift profit and ...

CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...

Eli Lilly & Co. has joined forces with artificial intelligence chipmaker Nvidia Corp. to develop what the companies describe as the most powerful supercomputer operated by a pharmaceutical firm. The ...

LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and ...

A particularly noteworthy achievement emerged this quarter: Eli Lilly's tirzepatide franchise overtook Merck's cancer immunotherapy Keytruda to become the world's highest-grossing medication. This ...

A year after earning FDA approval for Kisunla, Eli Lilly is shining a light on the anti-amyloid Alzheimer’s disease therapy in its first branded campaign. The “Light Up Tomorrow” direct-to-consumer ...

Q3 2025 Management View David Ricks, Chairman, CEO & President, opened the call stating, "Q3 was another strong quarter for Lilly. We made progress across all our strategic deliverables. We delivered ...

Lilly predicts it will achieve an adjusted profit of between $23.00 and $23.70 per share this year, an increase on its ...

US pharma major Eli Lilly today announced its financial results for the third-quarter of 2025, exceeding expectations and ...

Lina Polimeni was promoted to SVP and chief marketing office, consumer at Eli Lilly. Citrus Health Group, a 2025 MM+M Agency 100 honoree, hired Lisa Druce as chief client officer. Ardelyx appointed ...

Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multistate battle to stop sales of replica ...